Key result
Plasma paroxetine concentrations were negatively associated with clinical improvement in major depressive disorder (r = -0.282, p < 0.01), with response occurring at an upper threshold of 64.2 ng/ml.
Why the study?
Does plasma paroxetine concentration correlate with clinical improvement in patients with major depressive disorders?
Observational (n=120)
Does plasma paroxetine concentration correlate with clinical improvement in patients with major depressive disorders?
Effect estimate: r = -0.282
p-value: p=< 0.01
Higher plasma paroxetine concentrations are inversely correlated with clinical improvement in major depressive disorder, suggesting a therapeutic upper threshold.
No takes yet. Share an insight, caveat, or question.
May indicate need to avoid high paroxetine concentrations in MDD; leaves open whether monitoring improves outcomes.
Yasui‐Furukori et al. (2011) conducted an observational in Major depressive disorders (n=120). Paroxetine was evaluated on Percentage improvement in the total MADRS scores (r = -0.282, p=< 0.01). Plasma paroxetine concentrations were negatively associated with clinical improvement in major depressive disorder (r = -0.282, p < 0.01), with response occurring at an upper threshold of 64.2 ng/ml.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: